Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months.
After a baseline visit, patient returns for a control visit after 3 and 6 months of
treatment. One reference lesion is clinically evaluated with pictures.